||anti-Cre recombinase mAb;
||Cre-recombinase is a 38 kDa DNA recombinase derived from the P1 bacteriophage. It is highly specific to a 34 bp DNA sequence (loxP) found in P1 DNA. It catalyzes site-specific recombination between two 34-base-pair LOXP sites. Its role is to maintain the phage genome as a monomeric unit-copy plasmid in the lysogenic state. It is homotetramer when bound to DNA and belongs to the phage integrase family.
GenScript Mouse Anti-Cre recombinase Monoclonal Antibody is an important tool for the identification of recombinant Cre recombinase from E.coli expression systems.
||Spleen cells are fused with SP2/0-Ag14 mouse myeloma cells
||Protein A affinity column
||0.5 mg/ml, lyophilized with PBS, pH 7.4, containing 1% BSA and 0.02% sodium azide
||Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
||Recombinant Cre recombinase from E.coli expression systems.
||The antibody is stable in lyophilized form if stored at -20°C or below. The reconstituted antibody can be stored for 2-3 weeks at 2-8°C. For long term storage, aliquot and store at -20°C or below. Avoid repeated freezing and thawing cycles.
|Working concentrations for specific applications should be determined by the investigator. The chart below may serve as a useful guideline, but secondary antibody affinity, antigen concentration, temperature, incubation time, and the sensitivity of the detection methods can all affect the ideal working concentration. We have not yet determined the suitability of this antibody for other applications. The following concentration ranges are recommended starting points for this product.
ELISA: 0.05-0.2 µg/ml
Western blot: 0.1-1.0 µg/ml
Other applications: user-optimized
Western Blot Protocol(pdf)
Lin H.,et al. Establishment and characterization of a tamoxifen-mediated reversible immortalized mouse dental papilla cell line.In Vitro Cell Dev Biol Anim.2013Feb;49(2):114-121
Kaushik S.,et al. Loss of autophagy in hypothalamic POMC neurons impairs lipolysis.EMBO Rep.2012Mar;13(3):258-65